Nonsteroidal anti-inflammatory drugs: Effects on mortality after colorectal cancer diagnosis

Cancer

Volumn 115, Issue 24, 2009, Pages 5662-5671

  Zell, Jason A ^a,b   Ziogas, Argyrios ^a   Bernstein, Leslie ^c   Clarke, Christina A ^d   Deapen, Dennis ^e   Largent, Joan A ^a   Neuhausen, Susan L ^a   Stram, Daniel O ^e   Ursin, Giske ^e   Anton Culver, Hoda ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d NORTHERN CALIFORNIA CANCER CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Colon cancer; Colorectal cancer; Nonsteroidal anti inflammatory drugs; Rectal cancer; Survival

Indexed keywords

ACETYLSALICYLIC ACID; ANACIN; EXCEDRIN; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT DURATION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED;

EID: 73149089476     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24705     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res.1987;47:5340-5346.
3. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res.1996;56:2556-2560.
4. Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology. 1998;114:873-877.
5. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res.2000;60:5040-5044.
6. Reddy BS. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen.2004;44:26-35.
7. Hu Y, Le Leu RK, Young GP. Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice. Int J Cancer. 2005;116:870-875.
8. Zell JA, Ignatenko NA, Yerushalmi HF, et al. Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. Int J Cancer. 2007;120:459-468.
9. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991;101:635-639.
10. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med.1993;328:1313-1316.
11. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell-proliferation in patients with familial adenomatous polyposis. Br J Surg.1993;80:1618-1619.
12. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med.2000;342:1946-1952.
13. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res.2003;9:4756-4760.
14. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.
15. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med.2003;348:883-890.
16. Asano TK, McLeod RS. Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum. 2004;47:665-673.
17. Chan AT, Giovannucci EL, Schernhammer ES, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med.2004;140:157-166.
18. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med.2005;352:2184-2192.
19. Raju R, Cruz-Correa M. Chemoprevention of colorectal cancer. Dis Colon Rectum.2006;49:113-124.
20. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA.2005;294:914-923.
21. Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Non-steroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev.2006;15:1785- 1790.
22. Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal anti inflammatory drugs: a review. Cancer.2002;94:950-963.
23. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst.2007;99:608-615.
24. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med.1994;121:241-246.
25. Fuchs C, Meyerhardt JA, Heseltine DL, et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from Intergroup trial CALGB 89803. J Clin Oncol.2005;23(16 suppl pt I):3530.
26. Bernstein L, Allen M, Anton-Culver H, et al. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control.2002;13:625-635.
27. Kwong S, Perkin C, Morris C, Cohen R, Allen M, Wright W. Cancer in California: 1988-1999. Sacramento, CA: California Department of Health Services, Cancer Surveillance Section; 2001.
28. Fritz A, Percy C, Jack A, Shanmugaratnam K, Parkin DM, Whelan S. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
29. Horn-Ross PL, Hoggatt KJ, West DW, et al. Recent diet and breast cancer risk: the California Teachers Study (USA). Cancer Causes Control.2002;13: 407-415.
30. Young J, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. SEER Summary Staging Manual - 2000: Codes and Coding Instructions. Bethesda, Md: National Cancer Institute; 2001.
31. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology.1994;107:1183-1188.
32. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest.1997;99:2254-2259.
33. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med.2007;356:2131-2142.
34. Blanke CD, Mattek NC, Deloughery TG, Koop DR. A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer. Prostaglandins Other Lipid Mediat.2005;75:169-172.
35. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol.2005;23:2840-2855.
36. Blanke CD. Celecoxib with chemotherapy in colorectal cancer. Oncology (Williston Park).2002;16(4 suppl 3):17-21.
37. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol.2001;2:544-551.
38. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med.2006;355:873-884.
39. Solomon SD, Pfeffer MA, McMurray JJV, et al. Effect of celecoxib on cardiovascular events and blood pressure in 2 trials for the prevention of colorectal adenomas. Circulation. 2006;114:1028-1035.
40. Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med.2007;146:376-389.
41. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994;331:1669-1674.
42. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96:2992-3003.
43. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol Rev. 1993;15:499-545.
44. Slattery ML, Kerber RA. Family history of cancer and colon cancer risk: the Utah Population Database. J Natl Cancer Inst.1994;86:1618-1626.
45. Kune GA, Kune S, Watson LF. The effect of family history of cancer, religion, parity and migrant status on survival in colorectal cancer. Eur J Cancer.1992;28:1484-1487.
46. Slattery ML, Kerber RA. The impact of family history of colon cancer on survival after diagnosis with colon cancer. Int J Epidemiol.1995;24:888- 896.
47. Bass AJ, Meyerhardt JA, Chan JA, Giovannucci EL, Fuchs CS. Family history and survival after colorectal cancer diagnosis. Cancer. 2008;112:1222-1229.
48. Registry Committee, Japanese Research Society for Cancer of the Colon and Rectum. Clinical and pathological analyses of patients with a family history of colorectal cancer. Jpn J Clin Oncol.1993;23:342-349.
49. Chan JA, Meyerhardt JA, Niedzwiecki D, et al. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA. 2008;299:2515-2523.
50. Zell JA, Honda J, Ziogas A, Anton-Culver H. Survival after colorectal cancer diagnosis is associated with colorectal cancer family history. Cancer Epidemiol Biomarkers Prev. 2008;17:3134-3140.